I received my Ph.D. in Molecular Biology and Biochemistry from the University of Glasgow, UK and was a Human Frontier Fellow at the Dana Farber Cancer Institute, Harvard Medical School. I also worked as a lab head & project leader at Schering Plough and Novartis Research Institute. Before AstraZeneca, I was a senior investigator at Novartis Institute of BioMedical Research and have broad research interests and expertise in cancer biology and oncology therapeutics, including cancer genomics and epigenetics, the DNA damage response and drug resistance. I also have extensive experience in the discovery and development of targeted molecular therapeutics.

Technological advances are furthering our understanding of epigenetics - the science of how genomes are interpreted and expressed - and how these advances can lead to cancer or cause resistance to anticancer therapies. It is exciting to be at the forefront of revolutionary change in epigenomic capabilities and inhibitors targeting key processes, including chromatin remodeling and RNA modification, that will advance the next wave of innovation in cancer treatment.

Ho Man Chan Head of Epigenetics, Research & Development

CURRENT ROLE

Head of Epigenetics

2016-2020

Held multiple roles at Foghorn Therapeutics rising to Vice President, Head of Oncology and Translation Medicine

2007 - 2016

Increasing levels of scientific research at Novartis within epigenetics drug discovery and cancer programs, building platform and identifying novel targets in epigenetics

2006 - 2007

Senior Scientist at Schering Plough

Featured publications

Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies

Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies: Centore RC, Sandoval GJ, Soares LMM, Kadoch C, Chan HM. Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies. Trends Genet. 2020 Dec;36(12):936-950. doi: 10.1016/j.tig.2020.07.011. Epub 2020 Aug 29. PMID: 32873422.
Link: http://pubmed.ncbi.nlm.nih.gov/32873422/

A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation

A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation: Michel BC, D'Avino AR, Cassel SH, et al. complex is a synthetic lethal target in cancers driven by BAF complex perturbation. Nat Cell Biol. 2018;20(12):1410-1420. doi:10.1038/s41556-018-0221-1
Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698386/

Veeva ID: Z4-40999
Date of preparation: March 2022